Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

Benzonatate Dose Tolerance Study

Phase 1

Completed

Conditions: Cough

Interventions: Drug: Placebo
Drug: Benzonatate - 400 mg
Drug: Benzonatate - 600 mg

First Posted Date: 2012-09-24

Last Posted Date: 2012-09-24

Lead Sponsor: Pfizer

Target Recruit Count: 9

Registration Number: NCT01690975

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study In Healthy People To Evaluate Safety, Toleration And Time Course Of Plasma Concentration Of Multiple Oral Doses Of PF-04895162

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: PF-04895162
Drug: Placebo

First Posted Date: 2012-09-24

Last Posted Date: 2013-03-28

Lead Sponsor: Pfizer

Target Recruit Count: 10

Registration Number: NCT01691274

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Formation of Antibodies and Subsequent Prediction of Clinical Response in Patients With Rheumatoid Arthritis Treated With Four TNF Blocking Agents

Terminated

Conditions: Rheumatoid Arthritis (RA)

Interventions: Other: non-interventional study

First Posted Date: 2012-09-24

Last Posted Date: 2016-12-29

Lead Sponsor: Pfizer

Target Recruit Count: 79

Registration Number: NCT01691014

Locations: 🇩🇰
Gentofte Hospital, Medicinsk afd. C, Hellerup, Denmark
🇩🇰
Hillerod Hospital/Reumatologisk Afdeling, Hillerod, Denmark
🇩🇰
Odense Universitets Hospital/Reumatologisk Afdeling C, Odense C, Denmark

and more 10 locations

To Investigate the Safety and Tolerability of Aztreonam-Avibactam (ATM-AVI)

Phase 1

Completed

Conditions: Bacterial Infections
Complicated Infection

Interventions: Drug: Avibactam (AVI)
Drug: Aztreonam (ATM)
Drug: combination of Aztreonam - Avibactam (ATM-AVI)
Drug: Placebo

First Posted Date: 2012-09-21

Last Posted Date: 2017-09-06

Lead Sponsor: Pfizer

Target Recruit Count: 222

Registration Number: NCT01689207

Locations: 🇬🇧
Research Site, London, United Kingdom

A Study Comparing PF-05089771 TS Capsule To PF-05089771 TS Oral Dispersion In The Fasted State

Phase 1

Completed

Conditions: Pain

Interventions: Drug: PF-05089771

First Posted Date: 2012-09-21

Last Posted Date: 2012-12-12

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01690351

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study Of Oral Palbociclib (PD-0332991), A CDK4/6 Inhibitor, As Single Agent In Japanese Patients With Advanced Solid Tumors Or In Combination With Letrozole For The First-Line Treatment Of Postmenopausal Japanese Patients With ER (+) HER2 (-) Advanced Breast Cancer

Phase 2

Completed

Conditions: Breast Neoplasms
Neoplasms

Interventions: Drug: PD-0332991
Drug: letrozole

First Posted Date: 2012-09-12

Last Posted Date: 2020-11-23

Lead Sponsor: Pfizer

Target Recruit Count: 61

Registration Number: NCT01684215

Locations: 🇯🇵
Aichi Cancer Center Hospital, Nagoya, Aichi, Japan
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan
🇯🇵
National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido, Japan

and more 13 locations

Diflucan Research For Infant Evaluation Of Antifungal Treatment And Prophylaxis Medication

Completed

Conditions: Deep Mycosis

Interventions: Drug: Fluconazole

First Posted Date: 2012-09-07

Last Posted Date: 2021-07-19

Lead Sponsor: Pfizer

Target Recruit Count: 30

Registration Number: NCT01680458

A Randomized, Two-way, Crossover Study to Estimate the Relative Bioavailability of a Controlled-release Formulation of Oxycodone (40 mg) With Sequestered Naltrexone Compared With Immediate-release Oxycodone Tablets (20 mg) in Healthy Volunteers

Completed

Conditions: Healthy

Interventions: Drug: Oxycodone controlled-release test formulation
Drug: Immediate-release reference drug

First Posted Date: 2012-08-31

Last Posted Date: 2018-09-28

Lead Sponsor: Pfizer

Target Recruit Count: 14

Registration Number: NCT01677065

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

Study to Determine the Effects of Co-Administration of Alcohol on the Absorption of Oxycodone From a Proprietary Controlled-Release Formulation

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Test formulation administered with water
Drug: Test formulation administered with 20% ethanol
Drug: Test formulation administered with 40% ethanol

First Posted Date: 2012-08-31

Last Posted Date: 2012-12-11

Lead Sponsor: Pfizer

Target Recruit Count: 19

Registration Number: NCT01677039

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Phase 1

Completed

Conditions: Smoking
Vaccines

Interventions: Biological: NIC7-003
Biological: NIC7-001
Biological: Saline

First Posted Date: 2012-08-27

Last Posted Date: 2016-01-26

Lead Sponsor: Pfizer

Target Recruit Count: 277

Registration Number: NCT01672645

Locations: 🇨🇦
INC Research Toronto Inc., Toronto, Ontario, Canada
🇨🇦
Diex Research Montreal, Inc., Montreal, Quebec, Canada
🇨🇦
Diex Research Sherbrooke Inc., Sherbrooke, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy